Serum interleukin-18 and soluble tumour necrosis factor receptor 2 are associated with disease severity in patients with paracoccidioidomycosis

Clinical and Experimental Immunology

Volumn 147, Issue 3, 2007, Pages 483-490

  Corvino, C L ^a   Mamoni, R L ^a   Fagundes, G Z Z ^a   Blotta, M H S L ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Chemokines; IL 18; Paracoccidioidomycosis; sICAM 1; sTNF RII

Indexed keywords

ANTIFUNGAL AGENT; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 8; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SOUTH AMERICAN BLASTOMYCOSIS; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, FUNGAL; ANTIFUNGAL AGENTS; BIOLOGICAL MARKERS; CHEMOKINES; CHILD; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; INTERLEUKIN-18; MALE; MIDDLE AGED; PARACOCCIDIOIDES; PARACOCCIDIOIDOMYCOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RETROSPECTIVE STUDIES; SOLUBILITY;

EID: 33846821775     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03308.x     Document Type: Article

References (46)

1. Franco M, Peracoli MT, Soares A et al. Host-parasite relationship in paracoccidioidomycosis. Curr Top Med Mycol 1993; 5:115-49.
2. Franco M, Montenegro MR, Mendes RP et al. Paracoccidioidomycosis: a recently proposed classification of its clinical forms. Rev Soc Bras Med Trop 1987; 20:129-32.
3. Franco M. Host-parasite relationships in paracoccidioidomycosis. J Med Vet Mycol 1987; 25:5-18.
4. Okamura H, Tsutsi H, Komatsu T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995; 378:88-91.
5. Okamura H, Tsutsui H, Kashiwamura S et al. Interleukin-18: a novel cytokine that augments both innate and acquired immunity. Adv Immunol 1998; 70:281-312.
6. Robinson D, Shibuya K, Mui A et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 1997; 7:571-81.
7. Yoshimoto T, Takeda K, Tanaka T et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998; 161:3400-7.
8. Gracie JA, Forsey RJ, Chan WL et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104:1393-401.
9. Yamano T, Higashi T, Nouso K et al. Serum interferon-gamma- inducing factor/IL-18 levels in primary biliary cirrhosis. Clin Exp Immunol 2000; 122:227-31.
10. Monteleone G, Trapasso F, Parrello T et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol 1999; 163:143-7.
11. Park MC, Park YB, Lee SK. Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus. Clin Rheumatol 2004; 23:225-9.
12. Hoshino T, Wiltrout RH, Young HA. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J Immunol 1999; 162:5070-7.
13. Yoshimoto T, Mizutani H, Tsutsui H et al. IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol 2000; 1:132-7.
14. Kumano K, Nakao A, Nakajima H et al. Interleukin-18 enhances antigen-induced eosinophil recruitment into the mouse airways. Am J Respir Crit Care Med 1999; 160:873-8.
15. Mamoni RL, Nouer SA, Oliveira SJ et al. Enhanced production of specific IgG4, IgE, IgA and TGF-beta in sera from patients with the juvenile form of paracoccidioidomycosis. Med Mycol 2002; 40:153-9.
16. Mamoni RL, Rossi CL, Camargo ZP et al. Capture enzyme-linked immunosorbent assay to detect specific immunoglobulin E in sera of patients with paracoccidioidomycosis. Am J Trop Med Hyg 2001; 65:237-41.
17. Oliveira SJ, Mamoni RL, Musatti CC et al. Cytokines and lymphocyte proliferation in juvenile and adult forms of paracoccidioidomycosis: comparison with infected and non-infected controls. Microbes Infect 2002; 4:139-44.
18. Mamoni RL, Blotta MH. Kinetics of cytokines and chemokines gene expression distinguishes Paracoccidioides brasiliensis infection from disease. Cytokine 2005; 32:20-9.
19. Mamoni RL, Blotta MH. Flow-cytometric analysis of cytokine production in human paracoccidioidomycosis. Cytokine 2006; 35:207-16.
20. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84:2068-101.
21. Dustin ML, Rothlein R, Bhan AK et al. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137:245-54.
22. Stuyt RJ, Netea MG, Geijtenbeek TB et al. Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18 and interleukin-12 on human monocytes. Immunology 2003; 110:329-34.
23. Figueiredo F, Alves LM, Silva CL. Tumour necrosis factor production in vivo and in vitro in response to Paracoccidioides brasiliensis and the cell wall fractions thereof. Clin Exp Immunol 1993; 93:189-94.
24. Neworal EP, Altemani A, Mamoni RL et al. Immunocytochemical localization of cytokines and inducible nitric oxide synthase (iNOS) in oral mucosa and lymph nodes of patients with paracoccidioidomycosis. Cytokine 2003; 21:234-41.
25. Silva CL, Figueiredo F. Tumor necrosis factor in paracoccidioidomycosis patients. J Infect Dis 1991; 164:1033-4.
26. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996; 7:231-40.
27. Tai DI, Tsai SL, Chen TC et al. Modulation of tumor necrosis factor receptors 1 and 2 in chronic hepatitis B and C. the differences and implications in pathogenesis. J Biomed Sci 2001; 8:321-7.
28. Itoh Y, Okanoue T, Ohnishi N et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1999; 94:1332-40.
29. Van Zee KJ, Kohno T, Fischer E et al. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89:4845-9.
30. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354:610-21.
31. Fornazim MC, Balthazar A, Quagliato R Jr et al. Evaluation of bronchoalveolar cells in pulmonary paracoccidioidomycosis. Eur Respir J 2003; 22:895-9.
32. Souto JT, Aliberti JC, Campanelli AP et al. Chemokine production and leukocyte recruitment to the lungs of Paracoccidioides brasiliensis-infected mice is modulated by interferon-gamma. Am J Pathol 2003; 163:583-90.
33. Calich VLG, Blotta MHSL. Pulmonary paracoccidioidomycosis. In: Fidel PL, Huffnagle GB, eds. Fungal immunology: from organ perspective. New York: Springer, 2005:201-27.
34. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103:11-24.
35. Panagio LA. Paracoccidioidomycotic granuloma: protective immunity depends on cellular and humoral interaction in Paracoccidioides brasiliensis infection. PhD thesis. University of Sao Paulo, Brazil, 2006.
36. Benard G, Orii NM, Marques HH et al. Severe acute paracoccidioidomycosis in children. Pediatr Infect Dis J 1994; 13:510-5.
37. Calich VL, Kashino SS. Cytokines produced by susceptible and resistant mice in the course of Paracoccidioides brasiliensis infection. Brazil J Med Biol Res 1998; 31:615-23.
38. Pina A, Saldiva PH, Restrepo LE et al. Neutrophil role in pulmonary paracoccidioidomycosis depends on the resistance pattern of hosts. J Leukoc Biol 2006; 79:1202-13.
39. Arruda C, Franco MF, Kashino SS et al. Interleukin-12 protects mice against disseminated infection caused by Paracoccidioides brasiliensis but enhances pulmonary inflammation. Clin Immunol 2002; 103:185-95.
40. Yao HP, Xia DJ, Zhang LH et al. [Serum levels of sFas, sICAM-1, IL-18 in patients with chronic hepatitis C and their clinical significance]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2002; 31:2-5.
41. Huang ZS, Chiang BL, Hsu KL. Serum level of soluble tumor necrosis factor receptor II (sTNF-R75) is apparently an index of overall monocyte-related infectious and inflammatory activity. Am J Med Sci 2000; 320:183-7.
42. Liao F, Rabin RL, Yannelli JR et al. Human Mig chemokine: biochemical and functional characterization. J Exp Med 1995; 182:1301-14.
43. Loetscher M, Gerber B, Loetscher P et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 1996; 184:963-9.
44. Farber JM. Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 1997; 61:246-57.
45. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 2005; 41 (Suppl. 3):S189-93.
46. Romano CC, Mendes-Giannini MJ, Duarte AJ et al. IL-12 and neutralization of endogenous IL-10 revert the in vitro antigen-specific cellular immunosuppression of paracoccidioidomycosis patients. Cytokine 2002; 18:149-57.